Abstract Number: 645 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Background/Purpose: SLE is a multifaceted autoimmune disease denoted by immune dysregulation that contributes to increased morbidity and mortality in part due to infectious complications. Vaccination…Abstract Number: 646 • 2012 ACR/ARHP Annual Meeting
Comparison of the Lupusqol and SF-36 Scores As Valid Measures of Change in Health Related Quality of Life
Background/Purpose: The LupusQoL questionnaire is a disease-specific instrument for adults with lupus while the short form-36 (SF-36) is a generic questionnaire. We aimed to compare…Abstract Number: 647 • 2012 ACR/ARHP Annual Meeting
Adjusted Framingham Risk Factor Scoring for Systemic Lupus Erythematosus: Results from an Inception Cohort Followed for Eight Years
Background/Purpose : There is a high prevalence of premature atherosclerosis among patients with SLE, with a risk 7-9 times that of the general population. The…Abstract Number: 648 • 2012 ACR/ARHP Annual Meeting
Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus: Incidence Over a Ten Year Period
Background/Purpose: A large multicentre multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. The purpose of this study was to…Abstract Number: 649 • 2012 ACR/ARHP Annual Meeting
Increased Male-to-Female Ratio in Children Born to Women with Systemic Lupus Erythematosus
Background/Purpose: Recent experimental evidence suggests that anti-DNA antibodies, cross-reacting with brainstem neuronal receptors, induce apoptosis and cause a marked preferential loss of female foetuses in…Abstract Number: 650 • 2012 ACR/ARHP Annual Meeting
Clinical Variables Associated with Thrombosis At Systemic Lupus Erythematosus Diagnosis. Differences Between Patients with Positive/Negative Lupus Anticoagulant
Background/Purpose: Thrombosis in patients with Systemic Lupus Erythematosus (SLE) is a major cause of morbidity, it occurs in 9-37%, at younger age, and it represents…Abstract Number: 611 • 2012 ACR/ARHP Annual Meeting
Impaired Diffusion Tensor Imaging Findings in the Corpus Callosum and Cingulum May Underlie Impaired Learning and Memory Abilities in Systemic Lupus Erythematosus
Background/Purpose: Memory impairment is prevalent in systemic lupus erythematosus (SLE), however the pathogenesis is unknown. In a previous functional Magnetic Resonance Imaging (MRI) study we…Abstract Number: 612 • 2012 ACR/ARHP Annual Meeting
Thrombosis Recurrence in Systemic Lupus Erythematosus Patients with and without Antiphospholipid Antibodies
Background/Purpose: To determine the outcome of thrombotic events in the presence and absence of antiphospholipid antibodies (aPL) in patients with systemic lupus erythematosus (SLE).…Abstract Number: 613 • 2012 ACR/ARHP Annual Meeting
Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: Syndecan-1(SDC1), a transmemebrane heparan-sulfate glycoprotein, is predominantly expressed by plasma cells and is a receptor for a proliferation-inducing ligand (APRIL). SDC-1 is readily shed…Abstract Number: 614 • 2012 ACR/ARHP Annual Meeting
Predictors of Systemic Lupus Erythematosus Flares: Baseline Disease Activity and Demographic Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials
Background/Purpose: Predicting which SLE patients are at increased risk for clinically meaningful flares may be useful in making management decisions. The purpose of this analysis was to…Abstract Number: 615 • 2012 ACR/ARHP Annual Meeting
Baseline Laboratory Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials Are Predictive of Severe Flare At 52 Weeks
Background/Purpose: Identification and validation of potential serologic biomarkers of clinically meaningful SLE flare are major unmet medical needs in clinical practice and trials. The purpose…Abstract Number: 616 • 2012 ACR/ARHP Annual Meeting
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Background/Purpose: Belimumab is a recombinant, human Ig-G1λ monoclonal antibody that binds and antagonizes the biological activity of soluble B-lymphocyte stimulator protein, a member of the…Abstract Number: 617 • 2012 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels Reflect Organ Damage in Systemic Lupus Erythematosus
Background/Purpose: Disease activity assessment in systemic lupus erythematosus (SLE) remains a challenge due to lack of reliable biomarkers and disease heterogeneity. Ongoing tissue inflammation can…Abstract Number: 618 • 2012 ACR/ARHP Annual Meeting
BAFF/BLyS Gene Expression Predicts Disease Activity in Systemic Lupus Erythematosis Over One Year
Background/Purpose: The search for a marker of SLE disease activity has included inflammatory markers, chemokines and gene signatures. We explored the ability of the BAFF…Abstract Number: 619 • 2012 ACR/ARHP Annual Meeting
Elevated Plasma Levels of CXCL2 and CXCL10 Have Distinct Predictive Value in Systemic Lupus Erythematosus
Background/Purpose: Serum levels of chemokines have been previously used as downstream markers of the interferon (IFN) pathway in SLE. CXCL2 (GROB) and CXCL10 (IP-10) have…